Drugs / KBP-5209
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02442414 | Apr 2015 → Nov 2019 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05885776 | Sep 2022 → Mar 2024 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03574402 | Jul 2018 → Dec 2022 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KBP-5209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02442414 ↗ |
| Known as | Pirotinib | “Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research” NCT05885776 ↗ |
| Route | Oral | “KBP-5209 administered orally once daily (QD)” NCT02442414 ↗ |